Absence of Association between Polymorphisms in the RING E3 Ubiquitin Protein Ligase Gene and Ex Vivo Susceptibility to Conventional Antimalarial Drugs in Plasmodium falciparum Isolates from Dakar, Senegal

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5010-3. doi: 10.1128/AAC.03105-15. Print 2016 Aug.

Abstract

The RING E3 ubiquitin protein ligase is crucial for facilitating the transfer of ubiquitin. The only polymorphism identified in the E3 ubiquitin protein ligase gene was the D113N mutation (62.5%) but was not significantly associated with the 50% inhibitory concentration (IC50) of conventional antimalarial drugs. However, some mutated isolates (D113N) present a trend of reduced susceptibility to piperaquine (P = 0.0938). To evaluate the association of D113N polymorphism with susceptibility to antimalarials, more isolates are necessary.

MeSH terms

  • Antimalarials / pharmacology*
  • Artemisinins / pharmacology
  • Artesunate
  • Chloroquine / analogs & derivatives
  • Chloroquine / pharmacology
  • Doxycycline / pharmacology
  • Ethanolamines / pharmacology
  • Fluorenes / pharmacology
  • Lumefantrine
  • Mefloquine / pharmacology
  • Naphthyridines / pharmacology
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / genetics*
  • Polymorphism, Genetic / genetics*
  • Quinine / pharmacology
  • Quinolines / pharmacology
  • Senegal
  • Ubiquitin-Protein Ligases / genetics*

Substances

  • Antimalarials
  • Artemisinins
  • Ethanolamines
  • Fluorenes
  • Naphthyridines
  • Quinolines
  • Artesunate
  • artenimol
  • Chloroquine
  • piperaquine
  • Quinine
  • Ubiquitin-Protein Ligases
  • Lumefantrine
  • Doxycycline
  • pyronaridine
  • Mefloquine
  • desethylchloroquine

Grants and funding

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.